Inhibition of complement in Guillain-Barré Syndrome: the ICA-GBS study

Davidson, A. I., Halstead, S. K., Goodfellow, J. A., Chavada, G., Mallik, A., Overell, J., Lunn, M. P., McConnachie, A. , van Doorn, P. and Willison, H. J. (2017) Inhibition of complement in Guillain-Barré Syndrome: the ICA-GBS study. Journal of the Peripheral Nervous System, 6, pp. 4-12. (doi:10.1111/jns.12194) (PMID:27801990)

[img]
Preview
Text
131370.pdf - Accepted Version

1MB

Abstract

The outcome of Guillain-Barré syndrome remains unchanged since plasma exchange and intravenous immunoglobulin were introduced over 20 years ago. Pathogenesis studies on GBS have identified the terminal component of complement cascade as a key disease mediator and therapeutic target. We report the first use of terminal complement pathway inhibition with eculizumab in humans with GBS. In a randomised, double-blind, placebo-controlled trial, 28 subjects eligible on the basis of GBS disability grade of at least 3 were screened, of whom 8 (29%) were randomised. Five received eculizumab for four weeks, alongside standard intravenous immunoglobulin treatment. The safety outcomes, monitored via adverse events capture, showed eculizumab to be well tolerated and safe when administered in conjunction with IVIg. Primary and secondary efficacy outcomes in the form of GBS disability scores, MRC sum scores, Rasch Overall Disability Scores and Overall Neuropathy Limitation Scores are reported descriptively. For the primary efficacy outcome at 4 weeks after recruitment, 2 of 2 placebo and 2 of 5 eculizumab-treated subjects had improved by 1 or more grades on the GBS disability score. Although the small sample size precludes a statistically meaningful analysis, these pilot data indicate further studies on complement inhibition in GBS are warranted.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Halstead, Dr Susan and McConnachie, Dr Alex and Overell, Dr James and Davidson, Dr Amy and Willison, Professor Hugh and Goodfellow, Mr John
Authors: Davidson, A. I., Halstead, S. K., Goodfellow, J. A., Chavada, G., Mallik, A., Overell, J., Lunn, M. P., McConnachie, A., van Doorn, P., and Willison, H. J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Journal of the Peripheral Nervous System
Publisher:Wiley
ISSN:1085-9489
ISSN (Online):1529-8027
Published Online:14 March 2016
Copyright Holders:Copyright © 2016 Peripheral Nerve Society
First Published:First published in Journal of the Peripheral Nervous System 6:4-12
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record